@biotechnology
All things biotech.
ID: 14442905
calendar_today19-04-2008 12:48:59
54,54K Tweet
57,57K Followers
3,3K Following
5 hours ago
🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358
a year ago
FDA Adcomm Calls for Changes in Perioperative Lung Cancer Trials dlvr.it/TB6Dfr
Roche to Accelerate Development of Obesity Assets from $2.7B Carmot Buy dlvr.it/TB6DlF
BMS Gets Q2 Beat, Raises Full-Year Guidance as Cost-Cutting Initiative Continues dlvr.it/TB6Dlh
Big Pharma Appears to Be Unfazed by IRA Drug Price Negotiations dlvr.it/TB6Dm5
EU Regulatory Panel Recommends Against Approval of Eisai, Biogen’s Leqembi for Alzheimer’s dlvr.it/TB6DmR
You Can Buy Meat Grown in a Lab in This Country dlvr.it/TB6ZJM
Adaptimmune Gears Up for Potential Approval of First-in-Class Engineered T Cell Therapy dlvr.it/TBBqrS
FDA Action Alert: Adaptimmune, Zevra, Lykos and scPharma dlvr.it/TBBqrW
Navigating Deaths During Clinical Trials dlvr.it/TBBqrZ
Merck’s Keytruda in Combo With Padcev Granted CHMP Positive Opinion in Urothelial Carcinoma dlvr.it/TBCwDh
AbbVie’s Skyrizi Wins EU Nod for Ulcerative Colitis, Helps to Weather Humira Patent Cliff dlvr.it/TBCwHL
FDA Flags Safety Risks of Compounded Versions of Novo’s Semaglutide, Reports Hospitalizations dlvr.it/TBCwJ8
WuXi AppTec Hit With Slight Drop in US Revenue as Threat of BIOSECURE Act Looms dlvr.it/TBDJ5M
Boehringer Buys Nerio Therapeutics for $1.3B to Boost Immuno-Oncology Pipeline dlvr.it/TBDJ8k
Ventyx Ends Development of TYK2 Inhibitor After Phase II Flop in Crohn’s Disease dlvr.it/TBHXZM
AstraZeneca’s Calquence Aces Phase III CLL Trial, Eyes Fixed-Duration Approval dlvr.it/TBHXbs
Novo Nordisk’s Ozempic Could Help Curb Cigarette Use in Diabetics: Study dlvr.it/TBHXcB
BioNTech, Regeneron’s mRNA Cancer Vaccine Combo Clears Phase II in Melanoma dlvr.it/TBHXcX
10 months ago
noagendashow.net/listen/1693
The enemy's gate is down.